Iovance Biotherapeutics (NASDAQ:IOVA) Given New $11.00 Price Target at Barclays

Iovance Biotherapeutics (NASDAQ:IOVA) had its target price lifted by stock analysts at Barclays from $10.00 to $11.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price suggests a potential upside of 160.11% from the company’s current price.

Several other research analysts have also recently issued reports on the company. Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price objective for the company in a research report on Wednesday. The Goldman Sachs Group reissued a “sell” rating and issued a $2.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Chardan Capital dropped their target price on Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, HC Wainwright lowered their price target on shares of Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

Iovance Biotherapeutics Stock Performance

Shares of IOVA stock traded up $0.45 during mid-day trading on Wednesday, hitting $4.23. 19,690,148 shares of the stock were exchanged, compared to its average volume of 12,902,813. The stock’s fifty day simple moving average is $2.64 and its two-hundred day simple moving average is $2.40. Iovance Biotherapeutics has a 12-month low of $1.64 and a 12-month high of $5.64. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of -3.53 and a beta of 0.76.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. The company had revenue of $86.77 million during the quarter, compared to analysts’ expectations of $81.61 million. Iovance Biotherapeutics had a negative return on equity of 55.24% and a negative net margin of 158.78%. On average, research analysts expect that Iovance Biotherapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Trading of Iovance Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada raised its position in Iovance Biotherapeutics by 161.2% in the first quarter. Royal Bank of Canada now owns 522,887 shares of the biotechnology company’s stock worth $1,740,000 after acquiring an additional 322,680 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Iovance Biotherapeutics by 279.0% in the 1st quarter. AQR Capital Management LLC now owns 59,540 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 43,829 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Iovance Biotherapeutics by 30.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,571,902 shares of the biotechnology company’s stock worth $18,554,000 after purchasing an additional 1,301,846 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Iovance Biotherapeutics by 202.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock valued at $19,239,000 after purchasing an additional 3,869,617 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in Iovance Biotherapeutics by 112.1% during the second quarter. Envestnet Asset Management Inc. now owns 47,466 shares of the biotechnology company’s stock worth $82,000 after buying an additional 25,083 shares in the last quarter. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics News Summary

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: FDA approval and program expansion — Lifileucel (Amtagvi) has secured FDA approval for metastatic melanoma, reported favorable real‑world response and safety data, obtained Fast Track designation in second‑line NSCLC, and Iovance plans expanded registrational trials. These developments move Amtagvi from a pipeline prospect toward commercial execution. Read More.
• Positive Sentiment: Strong early sarcoma data — A pilot TIL trial reported a 50% objective response rate in advanced soft‑tissue sarcomas (UPS/DDLPS), a meaningful signal in a small but addressable patient population that likely spurred buying interest. Read More.
• Positive Sentiment: Q4 beat and improved operational metrics — Q4 revenue (~$86.8–$87M) topped estimates and EPS loss (-$0.18) was narrower than expected; management highlighted margin improvement and accelerating Amtagvi adoption. These results reduce near‑term execution uncertainty. Read More.
• Positive Sentiment: Analyst upgrade and higher price target — Citizens/JMP upgraded Iovance from Market Perform to Market Outperform and set a $5 price target, signaling institutional confidence in commercial upside and providing an analyst‑driven catalyst. Read More.
• Neutral Sentiment: Heavy call option activity — Unusual buying of call options (large uptick in call volume) suggests speculative bullish positioning by traders but doesn’t guarantee sustained directional moves.
• Neutral Sentiment: Earnings call and coverage — Transcripts and previews provide additional read‑throughs on commercialization progress and guidance; useful for due diligence but not immediate price drivers on their own. Read More.
• Negative Sentiment: Profitability, cash runway and dilution risks remain — Analysts note Iovance is still unprofitable, faces manufacturing and adoption execution risks, and may not generate meaningful cash from Amtagvi before 2028; modeled cash runway into ~Q3 2027 implies potential dilution if uptake or partnerships lag. Read More.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.